Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12 months after hospital discharge: a prospective, cohort study in Moscow (StopCOVID).
Adults
COVID-19
COVID-19 sequelae
Children
Long COVID
PASC
Post-COVID-19 condition
Post-acute sequelae of SARS-CoV-2 infection
Prevalence
Risk factor
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
06 07 2022
06 07 2022
Historique:
received:
14
05
2022
accepted:
21
06
2022
entrez:
6
7
2022
pubmed:
7
7
2022
medline:
9
7
2022
Statut:
epublish
Résumé
Previous studies assessing the prevalence of COVID-19 sequelae in adults and children were performed in the absence of an agreed definition. We investigated prevalence of post-COVID-19 condition (PCC) (WHO definition), at 6- and 12-months follow-up, amongst previously hospitalised adults and children and assessed risk factors. Prospective cohort study of children and adults with confirmed COVID-19 in Moscow, hospitalised between April and August, 2020. Two follow-up telephone interviews, using the International Severe Acute Respiratory and Emerging Infection Consortium survey, were performed at 6 and 12 months after discharge. One thousand thirteen of 2509 (40%) of adults and 360 of 849 (42%) of children discharged participated in both the 6- and 12-month follow-ups. PCC prevalence was 50% (95% CI 47-53) in adults and 20% (95% CI 16-24) in children at 6 months, with decline to 34% (95% CI 31-37) and 11% (95% CI 8-14), respectively, at 12 months. In adults, female sex was associated with PCC at 6- and 12-month follow-up (OR 2.04, 95% CI 1.57 to 2.65) and (OR 2.04, 1.54 to 2.69), respectively. Pre-existing hypertension (OR 1.42, 1.04 to 1.94) was associated with post-COVID-19 condition at 12 months. In children, neurological comorbidities were associated with PCC both at 6 months (OR 4.38, 1.36 to 15.67) and 12 months (OR 8.96, 2.55 to 34.82) while allergic respiratory diseases were associated at 12 months (OR 2.66, 1.04 to 6.47). Although prevalence of PCC declined one year after discharge, one in three adults and one in ten children experienced ongoing sequelae. In adults, females and persons with pre-existing hypertension, and in children, persons with neurological comorbidities or allergic respiratory diseases are at higher risk of PCC.
Sections du résumé
BACKGROUND
Previous studies assessing the prevalence of COVID-19 sequelae in adults and children were performed in the absence of an agreed definition. We investigated prevalence of post-COVID-19 condition (PCC) (WHO definition), at 6- and 12-months follow-up, amongst previously hospitalised adults and children and assessed risk factors.
METHODS
Prospective cohort study of children and adults with confirmed COVID-19 in Moscow, hospitalised between April and August, 2020. Two follow-up telephone interviews, using the International Severe Acute Respiratory and Emerging Infection Consortium survey, were performed at 6 and 12 months after discharge.
RESULTS
One thousand thirteen of 2509 (40%) of adults and 360 of 849 (42%) of children discharged participated in both the 6- and 12-month follow-ups. PCC prevalence was 50% (95% CI 47-53) in adults and 20% (95% CI 16-24) in children at 6 months, with decline to 34% (95% CI 31-37) and 11% (95% CI 8-14), respectively, at 12 months. In adults, female sex was associated with PCC at 6- and 12-month follow-up (OR 2.04, 95% CI 1.57 to 2.65) and (OR 2.04, 1.54 to 2.69), respectively. Pre-existing hypertension (OR 1.42, 1.04 to 1.94) was associated with post-COVID-19 condition at 12 months. In children, neurological comorbidities were associated with PCC both at 6 months (OR 4.38, 1.36 to 15.67) and 12 months (OR 8.96, 2.55 to 34.82) while allergic respiratory diseases were associated at 12 months (OR 2.66, 1.04 to 6.47).
CONCLUSIONS
Although prevalence of PCC declined one year after discharge, one in three adults and one in ten children experienced ongoing sequelae. In adults, females and persons with pre-existing hypertension, and in children, persons with neurological comorbidities or allergic respiratory diseases are at higher risk of PCC.
Identifiants
pubmed: 35794549
doi: 10.1186/s12916-022-02448-4
pii: 10.1186/s12916-022-02448-4
pmc: PMC9257572
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
244Subventions
Organisme : Medical Research Council
ID : MC_PC_19026
Pays : United Kingdom
Investigateurs
Nikol Alekseeva
(N)
Elena Artigas
(E)
Asmik Avagyan
(A)
Lusine Baziyants
(L)
Anna Belkina
(A)
Anna Berbenyuk
(A)
Tatiana Bezbabicheva
(T)
Vadim Bezrukov
(V)
Semyon Bordyugov
(S)
Aleksandra Borisenko
(A)
Maria Bratukhina
(M)
Ekaterina Bugaiskaya
(E)
Julia Chayka
(J)
Yulia Cherdantseva
(Y)
Natalia Degtyareva
(N)
Olesya Druzhkova
(O)
Alexander Dubinin
(A)
Khalisa Elifkhanova
(K)
Dmitry Eliseev
(D)
Anastasia Ezhova
(A)
Aleksandra Frolova
(A)
Julia Ganieva
(J)
Anastasia Gorina
(A)
Cyrill Gorlenko
(C)
Elizaveta Gribaleva
(E)
Eliza Gudratova
(E)
Shabnam Ibragimova
(S)
Khadizhat Kabieva
(K)
Yulia Kalan
(Y)
Margarita Kalinina
(M)
Nadezhda Khitrina
(N)
Bogdan Kirillov
(B)
Herman Kiseljow
(H)
Maria Kislova
(M)
Natalya Kogut
(N)
Irina Konova
(I)
Mariia Korgunova
(M)
Anastasia Kotelnikova
(A)
Karina Kovygina
(K)
Alexandra Krupina
(A)
Anastasia Kuznetsova
(A)
Anna Kuznetsova
(A)
Baina Lavginova
(B)
Elza Lidjieva
(E)
Ekaterina Listovskaya
(E)
Maria Lobova
(M)
Maria Loshkareva
(M)
Ekaterina Lyubimova
(E)
Daria Mamchich
(D)
Nadezhda Markina
(N)
Anastasia Maystrenko
(A)
Aigun Mursalova
(A)
Evgeniy Nagornov
(E)
Anna Nartova
(A)
Daria Nikolaeva
(D)
Georgiy Novoselov
(G)
Marina Ogandzhanova
(M)
Anna Pavlenko
(A)
Olga Perekosova
(O)
Erika Porubayeva
(E)
Kristina Presnyakova
(K)
Anna Pushkareva
(A)
Olga Romanova
(O)
Philipp Roshchin
(P)
Diana Salakhova
(D)
Ilona Sarukhanyan
(I)
Victoria Savina
(V)
Jamilya Shatrova
(J)
Nataliya Shishkina
(N)
Anastasia Shvedova
(A)
Denis Smirnov
(D)
Veronika Solovieva
(V)
Olga Spasskaya
(O)
Olga Sukhodolskaya
(O)
Shakir Suleimanov
(S)
Nailya Urmantaeva
(N)
Olga Usalka
(O)
Valeria Ustyan
(V)
Yana Valieva
(Y)
Katerina Varaksina
(K)
Maria Varaksina
(M)
Ekaterina Varlamova
(E)
Maria Vodianova
(M)
Margarita Yegiyan
(M)
Margarita Zaikina
(M)
Anastasia Zorina
(A)
Elena Zuykova
(E)
Informations de copyright
© 2022. The Author(s).
Références
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
Clin Exp Allergy. 2021 Sep;51(9):1107-1120
pubmed: 34351016
JAMA Pediatr. 2021 Nov 1;175(11):1095-1096
pubmed: 34338711
PLoS Med. 2021 Sep 28;18(9):e1003773
pubmed: 34582441
Arch Dis Child. 2020 Dec 1;:
pubmed: 33262177
Pediatr Infect Dis J. 2021 Dec 1;40(12):e482-e487
pubmed: 34870392
BMJ. 2021 Jul 26;374:n1648
pubmed: 34312178
Lancet. 2020 Dec 12;396(10266):1861
pubmed: 33308453
Lancet Reg Health Eur. 2021 Sep;8:100186
pubmed: 34386785
J Infect. 2022 Feb;84(2):158-170
pubmed: 34813820
Clin Exp Allergy. 2022 Jan;52(1):7-9
pubmed: 34978737
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Eur Respir J. 2022 Feb 3;59(2):
pubmed: 34210789
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Lancet Infect Dis. 2022 Apr;22(4):e102-e107
pubmed: 34951953
BMJ Glob Health. 2021 Sep;6(9):
pubmed: 34580069
Lancet Respir Med. 2022 Jul;10(7):632-634
pubmed: 35525253
Acta Paediatr. 2021 Jul;110(7):2208-2211
pubmed: 33835507
Clin Infect Dis. 2021 Jul 1;73(1):1-11
pubmed: 33035307
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Nat Med. 2020 Dec;26(12):1803
pubmed: 33288947
Lancet. 2021 Aug 28;398(10302):747-758
pubmed: 34454673
Lancet Child Adolesc Health. 2022 Apr;6(4):230-239
pubmed: 35143770
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937